Once-Weekly 1.6mg/m2 Bortezomib BCD Regimen in Newly Diagnosed Multiple Myeloma: Better Response and Lower Incidence of Peripheral Neuropathy

被引：0

作者：

Li, Fangfang ^{[1
]}

Li, Hao ^{[1
]}

Li, Yubin ^{[1
]}

Zhan, Zhumei ^{[1
]}

Song, Wangshan ^{[1
]}

Li, Fanglin ^{[1
]}

Li, Xiangxin ^{[1
]}

Wang, Lingling ^{[1
]}

Wang, Yan ^{[1
]}

Wang, Luqun ^{[1
]}

机构：

[1] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Shandong, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

bortezomib; complete response; Multiple myeloma;

D O I：

10.1016/j.clml.2019.09.351

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-025

引用

页码：E211 / E211

页数：1

共 31 条

[21] MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Korde, Neha
Mastey, Donna
Mailankody, Sham
Hassoun, Hani
Lesokhin, Alexander M.
Smith, Eric L.
Lendvai, Nikoletta
Hultcrantz, Malin
Tavitian, Elizabet
Salcedo, Meghan
Sams, Allison
Diab, Victoria
Chung, David J.
Scordo, Michael
Lahoud, Oscar B.
Landau, Heather J.
Arcila, Maria E.
Giralt, Sergio
Ho, Caleb
Roshal, Mikhail
Devlin, Sean M.
Dogan, Ahmet
Landgren, Ola
BLOOD, 2018, 132
[22] Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Jose Lahuerta, Juan
Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Grande, Carlos
de la Rubia, Javier
Rosinol, Laura
Sureda, Anna
Garcia-Larana, Jose
Diaz-Mediavilla, Joaquin
Hernandez-Garcia, Miguel T.
Carrera, Dolores
Besalduch, Joan
de Arriba, Felipe
Oriol, Albert
Escoda, Lourdes
Garcia-Frade, Javier
Rivas-Gonzalez, Concepcion
Alegre, Adrian
Blade, Joan
San Miguel, Jesus F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1913 - 1920
[23] Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial
Tanaka, Keisuke
Toyota, Shigeo
Akiyama, Megumi
Wakimoto, Naoki
Nakamura, Yuichi
Najima, Yuho
Doki, Noriko
Kakihana, Kazuhiko
Igarashi, Aiko
Kobayashi, Takeshi
Ohashi, Kazuteru
Kudo, Daisuke
Shinagawa, Atsushi
Takano, Hina
Fujio, Takayuki
Okoshi, Yasushi
Hori, Mitsuo
Kumagai, Takashi
Saito, Tatsuya
Mukae, Junichi
Yamamoto, Koh
Tsutsumi, Ikuyo
Komeno, Takuya
Yoshida, Chikashi
Yamamoto, Masahide
Kojima, Hiroshi
ACTA HAEMATOLOGICA, 2019, 141 (02) : 111 - 118
[24] Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma.: Preliminary results of the IFM 9502 randomized trial.
Harousseau, JLM
Facon, T
Moreau, P
Michallet, M
Guilhot, F
Hulin, C
Doyen, C
François, S
Marit, G
Maloisel, F
Attal, M
BLOOD, 1999, 94 (10) : 713A - 713A
[25] Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
Moreau, P
Facon, T
Attal, M
Hulin, C
Michallet, M
Maloisel, F
Sotto, JJ
Guilhot, F
Marit, G
Doyen, C
Jaubert, A
Fuzibet, JG
François, S
Benboubker, L
Monconduit, M
Voillat, L
Macro, M
Berthou, C
Dorvaux, V
Pignon, B
Rio, B
Matthes, T
Casassus, P
Caillot, D
Najman, N
Grosbois, B
Bataille, R
Harousseau, JL
BLOOD, 2002, 99 (03) : 731 - 735
[26] A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients
Palumbo, Antonio
Cavallo, Federica
Hardan, Izhar
Ciccone, Giovannino
Larocca, Alessandra
Cavalli, Maide
Peccatori, Jacopo
Carella, Angelo Michele
Brioli, Annamaria
Cafro, Anna Maria
Patriarca, Francesca
Siniscalchi, Agostina
Pezzatti, Sara
Crippa, Claudia
Montefusco, Vittorio
Levi, Anna
Ruggeri, Marina
Caravita, Tommaso
Ben Yehuda, Dina
Di Raimondo, Francesco
Boccadoro, Mario
BLOOD, 2010, 116 (21) : 1471 - 1471
[27] Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
Abidi, Muneer H.
Agarwal, Rishi
Ayash, Lois
Deol, Abhinav
Al-Kadhimi, Zaid
Abrams, Judith
Cronin, Simon
Ventimiglia, Marie
Lum, Lawrence
Zonder, Jeffrey
Ratanatharathorn, Voravit
Uberti, Joseph
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (09) : 1455 - 1461
[28] Peripheral blood stem cell (PBSC) mobilization with DCEP, an effective regimen for high risk multiple myeloma (MM) and prompt engraftment after melphalan (MEL 200 mg/m2) based high dose therapy
Desikan, R
Siegel, D
Anaissie, E
Singhal, S
Mehta, J
Munshi, N
Spoon, D
Ayers, D
Barlogie, B
BLOOD, 1998, 92 (10) : 273A - 273A
[29] Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
Yong, Kwee
Popat, Rakesh
Wilson, William
Pang, Gavin
Jenner, Richard
De Tute, Ruth M.
Ramasamy, Karthik
Streetly, Matthew
Cavenagh, Jamie
Sive, Jonathan
Chapman, Michael
Bygrave, Ceri
Phillips, Beth
Chavda, Selina J.
Virchis, Andres E.
Benjamin, Reuben
Arnott, Sarah
Willis, Fenella
Hassan, Sandra
Moore, Sally
Clifton-Hadley, Laura
Owen, Roger G.
BLOOD, 2019, 134
[30] High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM)
van Rhee, Frits
Alsayed, Yazan
Cottler-Fox, Michele H.
Haessler, Jeff
Waheed, Sarah
Nair, Bijay
Crowley, John
Anaissie, Elias
Barlogie, Bart
BLOOD, 2009, 114 (22) : 1324 - 1325

← 1 2 3 4 →